


FAQ

Frequently Asked Questions

MIGLOU™





SECTION 1.

TECHNOLOGY & MECHANISM OF ACTION

Q1. What technology does MIGLOU use, and how does it work?

A. MIGLOU operates on 2.45 GHz Ultra High Frequency (UHF) — the microwave band — to generate controlled thermal energy within targeted tissue layers. At this frequency, the epidermis acts as a near-transparent medium, allowing energy to pass through the skin surface and concentrate selectively in the subdermal fat layer. Cell tissues vibrate gently under the electromagnetic field, generating heat from within. The result is precise, volumetric heating of the target zone while the epidermal surface is actively protected by the integrated contact cooling system (5°C).

Q2. What is UHF, and why does MIGLOU call it UHF rather than microwave?

A. UHF (Ultra High Frequency) is a designation for the electromagnetic spectrum spanning 300 MHz to 3 GHz. At 2.45 GHz, MIGLOU operates squarely within the UHF/microwave band — the same frequency used in standard microwave applications. We use the term UHF in our communications because it more accurately reflects the physics classification and avoids consumer confusion with domestic appliances. The underlying principle is the same: selective, depth-controlled electromagnetic heating.

Q3. How is MIGLOU different from conventional RF (Radio Frequency) devices?

A. The key difference is frequency — and frequency determines where energy is deposited in tissue.

Parameter	RF (Radio Frequency)	MIGLOU (UHF / 2.45 GHz)
Frequency Range	0.3 MHz – 1 GHz	2.45 GHz
Primary Energy Deposition	Epidermis / upper dermis	Subdermal fat layer
Penetration Efficiency	Limited — energy disperses near skin surface	Deep and selective
Burn Risk	Higher (surface heat accumulation)	Lower (energy bypasses epidermis)
Fat Targeting	Indirect / secondary	Primary target

RF energy is largely absorbed before reaching the hypodermis, creating heat buildup in the dermal layers. MIGLOU’s UHF energy transmits through the skin and concentrates where it matters — the subcutaneous fat — making fat reduction and body contouring far more efficient.

Disclaimer

The applications described in the FAQ (Frequently Asked Questions) in this guide are based on various clinical studies, academic literature, and a range of case experiences.

Treatment parameters must be adjusted according to individual patient conditions.

The manufacturer shall not be held responsible for any issues arising from improper use of the equipment or excessive treatment.

Prior to use, practitioners must review the user manual and fully understand the correct operation and handling of the device before performing any procedures.

The treatment protocol includes pre-treatment consultation (such as patient history assessment and lesion diagnosis), treatment procedures, number of sessions, expected outcomes, potential side effects, precautions for both practitioners and patients before and after treatment, informed consent, selection of appropriate treatment parameters, post-treatment care, medication prescriptions, and follow-up scheduling.

The indications and parameters provided in this booklet may be updated based on clinical experience and accumulated case data. Practitioners are advised to refer to the latest clinical updates when applying treatments.

Q4. What makes MIGLOU's energy delivery different from other microwave-based devices?

A. MIGLOU incorporates a proprietary patented technology called **FIM (Focused Intensive Microwave)** Smart Matching (Patent Application No. 10-2024-0046442). Unlike standard microwave emission where energy radiates broadly and disperses, FIM technology focuses and concentrates energy delivery precisely toward the target focal zone. This enhances both the intensity and efficiency of delivered energy per joule, meaning equivalent or superior clinical outcomes are achievable in a shorter treatment time compared to conventional microwave emission designs.

Q5. Is MIGLOU safe? Is there a risk from the electromagnetic emission?

A. Yes, MIGLOU is designed with multiple layers of safety architecture:

-
- Ⓞ **Electromagnetic Shielding Structure:** MIGLOU uses a superior internal shielding design that minimizes airborne electromagnetic leakage. Independent testing (IoT Technical Support Center, August 2025) confirmed that radiated power at 200W output measures only **0.10W** — comparable to a home Wi-Fi router.
 - Ⓞ **Contact Cooling System:** The handpiece-integrated cooling system maintains skin surface temperature between 5°C and 22°C throughout treatment, preventing thermal injury to the epidermis.
 - Ⓞ **Gyro Sensor / Safe Moving Sensor:** A built-in gyro sensor detects both contact with skin and handpiece movement. Emission is automatically controlled in real time, with 30 adjustable sensitivity levels — preventing energy delivery when the handpiece is lifted or improperly positioned.
 - Ⓞ **Emergency Button:** An emergency shutdown button immediately halts all system activity if required.
-

The electromagnetic risk of any device is primarily a function of output power, not frequency alone. MIGLOU's shielding and focusing technology ensure that energy remains where it is intended — within the target tissue — and is not radiated into the surrounding environment.

Q6. How is MIGLOU different from a microwave oven if both use 2.45 GHz?

A. A microwave oven emits energy freely via an uncontrolled antenna into a sealed metallic cavity, heating food uniformly and indiscriminately via water absorption. MIGLOU's emission is entirely different in nature:

-
- Ⓞ Energy is emitted through the handpiece tip in a controlled, focused pattern using FIM technology.
 - Ⓞ The shielding structure contains and directs the field exclusively toward the treatment target — not into the air or surrounding tissues.
 - Ⓞ The gyro sensor halts emission whenever contact with skin is broken.
 - Ⓞ Output power is precisely adjustable and does not exceed clinical need.
-


The result is a tightly controlled therapeutic tool — not an uncontrolled radiant source.

Q7. What tissue depths does MIGLOU treat?

A. MIGLOU offers three handpiece options with different focal depths optimized for different anatomical zones:

Handpiece	Focal Depth	Target Area	Primary Indication
LYFT (3mm)	3 mm	Facial dermis	Collagen remodeling, lifting, contouring
SHUEIP (7mm)	7 mm	Subdermal fat (face/body)	Fat reduction, tightening, cellulite
D-SHUEIP (12mm)	12 mm	Deep subcutaneous fat (body)	Deep fat reduction, body contouring

The 7, 12mm handpiece is recommended for areas with thicker subcutaneous fat; the 3mm handpiece is appropriate for areas with minimal fat depth.



SECTION 2.

CLINICAL EFFECTS & INDICATIONS

Q8. What clinical outcomes does MIGLOU target?

A. MIGLOU addresses five primary clinical indications:

1. **Neocollagenesis** — stimulation of new collagen production via fibroblast activation
2. **Skin Contour Improvement** — reshaping and defining facial and body contours
3. **Elasticity Enhancement** — tightening of lax or loose skin
4. **Lipolysis** — thermal disruption and breakdown of subcutaneous adipocytes
5. **Cellulite Treatment** — disruption of fibrous septae and improvement of surface texture

Q9. How does MIGLOU achieve fat reduction (lipolysis)?

A. At 2.45 GHz, UHF energy is selectively absorbed by subcutaneous fat tissue. The thermal effect elevates local tissue temperature to a level sufficient to disrupt adipocyte membranes and initiate lipolysis. Released lipids enter the interstitial space, where they are naturally processed and cleared through the lymphatic system over the weeks following treatment. This is a physiological, non-invasive pathway to fat reduction — no incisions, no suction, no cell freezing.

Q10. Can MIGLOU treat both face and body?

A. Yes. This is one of MIGLOU's defining advantages over body-only microwave platforms. The three-handpiece system supports both:

Facial applications (LYFT handpiece, 3mm)

- Jawline definition
- Double chin reduction
- Overall facial contouring
- Skin lifting and tightening



Body applications (SHUEIP 7mm / D-SHUEIP 12mm)

- Abdomen
- Flanks (love handles)
- Thighs
- Upper arms
- Calves
- Back



Q11. What is the mechanism for skin tightening and lifting?

A. Thermal energy delivered to the dermal and subdermal collagen network causes two effects. First, there is an immediate response: existing collagen fibers contract upon heating, producing an acute tightening effect. Second, over the following weeks, fibroblasts activated by the thermal stimulus produce new collagen — a process called neocollagenesis — resulting in progressive improvement in skin firmness and elasticity. The LYFT handpiece (3mm) is optimized for this indication on the face.


Q12. Can MIGLOU treat cellulite?

A. Yes. Cellulite results from adipocyte hypertrophy, fluid retention, and the formation of rigid fibrous collagen septae that tether skin downward while fat lobules push outward. MIGLOU addresses cellulite through:

-
1. Reducing the volume of adipocytes in the hypodermis, relieving pressure on the fibrous walls
 2. Applying thermal energy to the fibrous septae, triggering collagen solubilization and eventual remodeling into more elastic fibers — reducing the tethering effect that causes the dimpled surface appearance
-

Q13. How long do results last?

A. Clinical studies report effect maintenance of one year or longer following a complete treatment course (in case of 3-5 times session with 1 month interval). Long-term durability depends on the patient's lifestyle, metabolic condition, and post-treatment care. A healthy diet and regular physical activity are recommended to maintain results.



SECTION 3.

TREATMENT PROTOCOLS & PARAMETERS

Q14. What are the recommended treatment parameters for face and body?

A. The following table summarizes reference protocol parameters. Note that these are starting guidelines — the treating physician should perform a Test Shot and adjust settings based on individual patient response.

Face Protocols:

	Handpiece Power	Energy Target	Est. Time
Face 3mm / 7mm	80W	60,000 – 80,000 J	13 – 17 min
	90W	60,000 – 80,000 J	11 – 15 min
	100W	60,000 – 80,000 J	10 – 12 min

Body Protocols:

Body Part	Handpiece	Power	Energy Target	Est. Time
Abdomen	7mm	140 – 180W	120,000 J	11 – 14 min
Flank	7mm	130 – 150W	100,000 J	11 – 12 min
Thigh	7mm	140 – 180W	100,000 J	9 – 11 min
Calf	12mm	130 – 150W	70,000 J	7 – 8 min
Forearm	12mm	130 – 150W	60,000 J	6 – 7 min
Back	12mm	140 – 180W	100,000 J	9 – 11 min

For all protocols, skin cooling temperature should be set to 5°C at the start of treatment.

Q15. How many sessions are recommended, and at what intervals?

A.

Treatment Area	Interval	Recommended Sessions
Face	Every 3 - 4 weeks	3 - 4 sessions
Body	Every 4 - 5 weeks	5 - 6 sessions

Face treatments require shorter intervals due to the dynamics of gradual collagen remodeling. Body treatments require longer intervals to allow full metabolic processing and lymphatic clearance of disrupted fat.

Q16. How long is a typical treatment session?

A. A single treatment session generally takes **10 to 20 min (around 10~15m for face, 15~20 for body)** for standard areas. Actual time varies based on the area size, selected power level, and total energy dose target. Higher power settings deliver the required energy dose faster.

Q17. When do patients typically notice results?

A. Some improvement may be visible shortly after the first session, particularly for skin tightening. Contouring and fat reduction results generally become more apparent after 2-3 sessions. Full clinical outcomes — especially those driven by neocollagenesis — continue to develop over 1-3 months following the final session, as biological remodeling processes complete.

Q18. Can two different protocols be applied to the same area in one session?


A. It is not recommended to apply two Miglou consecutive but different protocols to the same area within a single session. If multiple concerns are present in the same zone, address the primary indication in the current session and treat secondary indications in subsequent sessions, respecting the recommended treatment interval.

Q19. Can MIGLOU be combined with other aesthetic treatments?

A. Yes. MIGLOU demonstrates synergistic effects when combined with the following procedures:

-
- **Skin boosters (especially those targeting the dermal layer)**
 - **ECM-based treatments**
 - **PDLLA injections**
 - **Skin Botox**
 - **Hyaluronic acid-based treatments**
-

For body treatments, combining fat reduction with concurrent elasticity improvement is a common and effective approach. Note: exercise caution with skin booster timing — consult the clinical protocol before combining. If surgical procedures have been performed in the treatment area, allow complete healing before applying MIGLOU.



SECTION 4.

SAFETY, CONTRAINDICATIONS & SIDE EFFECTS

Q20. What are the absolute contraindications for MIGLOU?

A. The following conditions represent absolute contraindications. Treatment must not proceed:

- Cardiac disorders or implanted cardiac devices (pacemakers, defibrillators)
- Severe vascular disease
- Active malignancy or history of malignancy within 5 years
- Hepatic or renal dysfunction
- Active phlebitis, thrombophlebitis, or phlebothrombosis
- Pregnancy or breastfeeding
- Active infectious disease (including hepatitis B/C)
- Clotting disorders or hemorrhagic conditions
- Organ transplant recipients
- Decompensated diabetes (Type I or II)
- Deep brain stimulation implants
- Recognized sensitivity to electromagnetic devices

Q21. What areas of the body are excluded from MIGLOU treatment?

A. The following anatomical areas must not be treated:

- Brain
- Eyes
- Thyroid region
- Heart / cardiac area / décolleté
- Major lymph node stations
- Navel (belly button) / genitalia
- Areas with tattoos or permanent makeup
- Bony prominences or areas with minimal subcutaneous fat (<1 cm)
- Areas with metal or permanent implants
- Open wounds, active inflammation, or infection
- Areas with vascular lesions (varicose veins)
- Mucous membranes

Note At 2.45 GHz, bone transmits very little microwave energy — most is reflected due to low water content and high density. The result is discomfort and potential periosteal heating with no therapeutic benefit. Avoid passing the handpiece directly over bony areas.

Q22. Are there relative contraindications that require physician judgment?

A. Yes. The following conditions require case-by-case evaluation by the treating physician before proceeding:

- Skin pathologies in the treatment area
 - Heat-sensitive conditions (e.g., active Herpes Simplex)
 - Anticoagulant or antiplatelet therapy (risk of persistent erythema)
 - Use of steroidal anti-inflammatories within one week pre-treatment
 - Retinoids, antioxidants, or skin supplement use within one month
 - History of phlebitis or thrombosis
 - Varicose veins in or near the treatment area
 - Autoimmune conditions
 - Diabetes (non-decompensated)
 - BMI considerations — MIGLOU is intended for localized adiposity, not general obesity
 - Abnormal blood pressure
 - Keloid-prone patients
-

Q23. What side effects can patients experience?

A. Commonly reported mild and transient side effects include:

- Warmth or heat sensation during and after treatment
 - Temporary redness or erythema in the treated area
 - Mild swelling or tenderness
 - Numbness or tingling sensation
 - Bruising (in some cases)
-

These reactions are typically self-resolving within a few days. Serious adverse events — including tissue necrosis, contour irregularity, or surface asymmetry — can occur if the device is misused (e.g., excessive energy application, incorrect patient selection, treating over contraindicated areas). Proper training and adherence to protocol are essential.

Q24. Is there any effect on lipid or blood parameters from repeated treatments?

A. Based on available clinical data, no significant alteration to blood lipid profiles has been observed following MIGLOU treatment courses. The lipids released through lipolysis are metabolically processed and cleared through the lymphatic system via normal physiological channels.

Q25. Can the handpiece be applied over areas with vascular lesions?

A. Minor capillaries are generally not a concern for MIGLOU treatment, as the energy is selective for fat rather than hemoglobin. However, varicose veins represent a contraindication. Telangiectasias present in the treatment zone may experience temporary worsening due to local heat — patients should be informed of this possibility. If a patient reports discomfort over capillary-dense areas, reduce handpiece pressure in that zone.

Q26. Can MIGLOU treat over a tattoo?

A. No. Tattoo pigments may contain metallic compounds with unknown electromagnetic absorption properties. Treating over a tattoo area creates unpredictable energy deposition and a risk of adverse skin reactions. Permanently tattooed or pigmented areas must be excluded from the treatment zone.

Q27. What about patients with metal implants in the treatment area?

A. Metal implants in or near the intended treatment area are a contraindication. The presence of metal can alter electromagnetic field distribution and cause localized overheating. If a metal implant is distant from the treatment zone, a physician evaluation is required before proceeding.



SECTION 5.

PRE-AND POST-TREATMENT CARE

Q28. What are the pre-treatment recommendations?

1. **Avoid hydrating creams and lotions** on the treatment area for at least one week before the session. Water content in topical products absorbs UHF energy at the skin surface, reducing the proportion reaching the fat layer.
2. **Shave dense hair** from the treatment area to ensure full handpiece-to-skin contact and coupling efficiency.
3. **Cleanse the treatment area** thoroughly — remove all makeup, deodorant, ointments, and residue before starting.
4. **Hydrate internally:** Patients should drink approximately 2 liters of water per day, starting the day before treatment and continuing through the day after. Adequate systemic hydration supports lymphatic drainage and metabolic clearance of disrupted fat.
5. Apply a thin layer of appropriate coupling gel or vaseline oil (pharmaceutical grade, water-free) over the treatment area immediately before starting to ensure smooth handpiece glide and optimal energy coupling.

Q29. What are the post-treatment recommendations?


- **Lymphatic drainage massage** is strongly recommended immediately following the session (1-2 minutes) to support clearance of treatment byproducts.
- Continue 1-2 lymphatic drainage sessions per week between treatment appointments.
- **Avoid direct sun exposure** for 48 hours following treatment to prevent erythema complications.
- If residual redness is present, **avoid hot showers** in the affected area until erythema fully subsides.
- Follow a **balanced diet and moderate exercise** routine to support and maintain treatment results.
- Do not re-treat the same area within the recommended minimum interval.

Q30. Does drinking water before and after treatment influence outcomes?

A. Yes. Systemic hydration supports faster lymphatic fluid movement and reduces post-treatment fluid retention. Patients who maintain good daily water intake tend to experience more efficient metabolic processing of released fat and improved clearance of post-treatment interstitial fluids.

Q31. What is the recommended interval between sessions on the same area?

A. Body treatments require a minimum of **3-4 weeks** between sessions. Face treatments require a minimum of **2-3, 3-4 weeks (up to the dermis Thickness)**. This interval is necessary to allow the body's metabolic and lymphatic systems to process treatment outputs before the next energy application. Treating too frequently risks overlapping effects with no additional benefit and potential tissue stress.



SECTION 6.

DEVICE & HANDPIECE FEATURES

Q32. What handpieces are included with MIGLOU, and what are their roles?

Handpiece	Diameter	Focal Depth	Primary Role
LYFT	Ø40mm	3mm	Facial lifting, jawline, double chin
SHUEIP	Ø56mm	7mm	Facial fat / body shaping, cellulite
D-SHUEIP	Ø66mm	12mm	Deep body fat reduction

All three handpieces feature:

- **1.54" onboard LCD screen** displaying handpiece type, energy setting (W), cumulative dose (kJ), elapsed time, and treatment mode (Standby / Ready / Emission)
- **Four-button control** panel (Energy Up / Energy Down / Ready / Emission) for full in-hand parameter management without returning to the console
- **LED indicator** for real-time status and energy delivery confirmation
- **Integrated contact cooling** system built seamlessly into the handpiece tip

Q33. What safety features are built into the handpiece itself?

A. The MIGLOU handpiece integrates two layers of protective sensing:

- 1. Contact Sensor:** Detects whether the handpiece tip is in adequate contact with the skin. Energy emission pauses automatically if full contact is not confirmed.
- 2. Gyro (Movement) Sensor:** Detects handpiece motion in real time. The moving sensor has 30 adjustable sensitivity levels, allowing clinicians to calibrate the system to their treatment speed. This prevents energy delivery during inadvertent lifts or incorrect positioning.

Together, these create a "**double protection**" system that significantly reduces the risk of overheating or unintended energy delivery.

Q34. What are the key features of the main console?

A.

-
- **12.1" Color Touch Display**, rotatable up to 60° for ergonomic positioning
 - **Smart GUI** with intuitive parameter setting: dose, power control, and one-touch handpiece synchronization
 - **Treatment Information System (TIS)**: Records each patient's treatment history, applied protocols, and responses. Enables data-driven protocol decisions for subsequent sessions.
 - **Remote Maintenance System (RMS)**: Supports built-in device diagnostics and performance monitoring for proactive maintenance and error prevention.
 - **180° articulating arm** for wide range of motion during treatment
 - **Emergency button** with automatic system shutdown capability
 - **Air vent system** with high-circulation airflow for thermal management
-

Q35. Does MIGLOU use consumables?

A. Yes, MIGLOU requires a proprietary coolant fluid specifically formulated for this system. The coolant has the following characteristics:

-
- Remains liquid down to -65°C
 - Does not absorb or interfere with UHF microwave energy transmission
 - Electrically insulating for safety compliance
-

The device uses approximately 2.5 kg of coolant per fill. Typical replacement frequency is approximately once per year based on standard clinical usage. Coolant replacement cost and availability vary by region — please contact your local distributor for details.

Q36. How long does the cooling system take to stabilize after startup?


A. MIGLOU's cooling system reaches stable operating temperature (5°C) within approximately **5 minutes** of device startup. Clinicians should allow this warm-up period before commencing treatment.

Q37. What is the warranty period for MIGLOU?

A. MIGLOU carries a standard **2-year device warranty**. This is double the warranty offered by the primary competing platform in this category.

Q38. What is the treatment time advantage of MIGLOU over comparable devices?

A. MIGLOU's FIM (Focused Intensive Microwaves) technology improves energy delivery efficiency compared to standard microwave emission architectures. As a result, MIGLOU achieves the target thermal dose in **7-12 minutes** per area, versus 10-15 minutes for the leading competing device. This allows clinicians to treat more patients per day without compromising clinical outcomes.



SECTION 7.

COMPETITIVE POSITIONING & REGULATORY

Q39. How does MIGLOU compare to the leading competing microwave device?

A.

Feature	MIGLOU™	Competitor
Frequency	2.45 GHz UHF	2.45 GHz
Handpiece Technology	FIM (focused Intensive Microwaves)	Coolwaves
Output Power Range	5 – 200W	50 – 200W
Handpiece Types	3 types (3mm / 7mm / 12mm)	2 types (3mm / 7mm)
Handpiece Display	1.54" LCD (energy, dose, time)	None
Handpiece Control	Full (Power / Ready / Emission)	Start / Stop only
Face Treatment	☑ (dedicated 3mm handpiece)	Limited
Safe Moving Sensor	☑ (30 adjustable levels)	X
EM Shielding	Superior structure	Standard
Treatment Time	7 – 12 min	10 – 15 min
Target Cooling Speed	5°C in 7 – 8 min	~10 – 15 min
TIS (Treatment History System)	☑	X
RMS (Remote Maintenance)	☑	X
Display Screen	12.1" Color Touch (rotatable)	10.4" (fixed)
Warranty	2 Years	1 Year

Q40. Is MIGLOU a copy of existing technology? Is there IP differentiation?

A. No. MIGLOU is built on Hironic’s own independent technology development. The core energy delivery mechanism — FIM (Focused Intensive Microwave) — is a proprietary and patent-applied innovation (Application No. 10-2024-0046442). While MIGLOU and the competing platform share the same operating frequency (2.45 GHz), the handpiece architecture, energy focusing methodology, and control systems are distinctly engineered solutions developed independently by Hironic Co., Ltd.

The 2.45 GHz ISM band is an internationally designated, openly available frequency for medical, scientific, and industrial applications — use of this frequency is not protectable, but the specific implementation methods are.

Q41. What regulatory certifications does MIGLOU currently hold?

A.

Certification	Status
KC (Korea)	☑ Obtained
MFDS (Korea MFDS)	In process
CE MDR (Europe)	Planned
FDA (United States)	In process

Device specifications and approved indications may vary by market depending on regional regulatory clearance. Please confirm applicable cleared indications with your local distributor.

Q42. Who is an ideal candidate for MIGLOU treatment?

A. MIGLOU is appropriate for patients who:

-
- Seek non-invasive fat reduction in localized areas (not general obesity)
 - Want visible skin tightening or lifting effects without surgery or significant downtime
 - Desire both facial contouring and body shaping from a single platform
 - Prefer a comfortable, painless treatment — no anesthesia required
 - Need to return to normal activities immediately following treatment
-

This document is for educational and sales reference purposes only.
Clinical protocols should be applied at the physician's discretion based on
individual patient assessment.
Indications and parameters may vary by country based on regulatory clearance.
For technical or clinical inquiries, contact Hironic Co., Ltd.